Breathe Well Live Well
|
Skyepharma launches Flutiform in France for asthma
The Pharma Letter UK drug delivery specialist Skyepharma (LSE: SKP) has received regulatory approval and agreement on pricing reimbursement for asthma treatment Flutiform in France. Skyepharma's licensee Mundipharma, responsible for the development and … Skyepharma Jumps As It Launches Flutiform in France |
View full post on asthma – Google News
|
KaloBios Pharma pulls plug on asthma drug, shares plunge
Reuters (Reuters) – Shares of KaloBios Pharmaceuticals Inc fell nearly 50 percent in extended trade after the company said it would stop developing an asthma drug that failed in a mid-stage study. The drug, KB003, failed to bring about a clinically meaningful … KaloBios stock slides; to stop asthma study KaloBios: KB003 Fails To Meet Primary Goal In Phase 2 Asthma Study |
View full post on asthma – Google News
|
Shares jump as Array BioPharma reports positive results for asthma drug
The Pharma Letter US biotech firm Array BioPharma (Nasdaq: ARRY) saw its shares jump as it announced that its drug candidate for mild to moderate persistent allergic asthma, ARRY-502, an oral CRTh2 antagonist, met all primary and secondary endpoints. The company said … |
View full post on asthma – Google News
|
Global asthma market to reach 159 million lifetime cases by 2022
The Pharma Letter Over 300 million people suffer from asthma, which translates to a drug market worth over $15 billion. While drugs to manage asthma have existed for several decades, pharmaceutical companies have developed faster acting and more effective products over … |
View full post on asthma – Google News
|
US pulmonologists view refractory asthma patient treatment with biosimilar …
The Pharma Letter US pulmonologists surveyed by health care advisory firm Decision Resources estimate that only 19% percent of their severe, refractory asthma patients are treated with Genentech and Novartis' Xolair (omalizumab), the only approved drug that serves this … |
View full post on asthma – Google News
|
Boehringer Ingelheim presents positive efficacy data for tiotropium in asthma …
The Pharma Letter German family-owned drug major Boehringer Ingelheim presented a new subset of data from the Phase III UniTinA-asthma program relating to its already-marketed drug Spiriva (tiotropium) at the 2013 American Academy of Allergy, Asthma & Immunology … Boehringer Ingelheim drug shows benefits in new asthma trial |
View full post on asthma – Google News
 Packaging World |
Aptar Pharma dose indicator selected for new asthma combination therapy
Packaging World It is indicated for the maintenance treatment of asthma in patients aged 12 years and over, and in adults whose symptoms are not adequately controlled on an ICS and an as-required inhaled short-acting beta2-agonist (SABA), and in those patients who are … |
View full post on asthma – Google News
|
Aptar Pharma dose indicator selected for new asthma combination therapy
Healthcare Packaging It is indicated for the maintenance treatment of asthma in patients aged 12 years and over (50/5?g and 125/5?g strengths), and in adults (250/10?g strength) whose symptoms are not adequately controlled on an ICS and an as-required inhaled short-acting … |
View full post on asthma – Google News
|
Asthma preventive drugs market led by GlaxoSmithKline's Advair
The Pharma Letter Asthma is a respiratory condition in which the airways become inflamed and constrict, usually in response to one or more environmental triggers. As a serious and potentially fatal condition if left untreated, asthma can be managed by avoiding triggers … |
View full post on asthma – Google News
|
Teijin Pharma inks bronchial asthma pact with Pulmagen
Pharma Times The number of people in Japan suffering from bronchial asthma has nearly doubled to more than eight million adults and children over the past 10 years. Although mortality is declining, more than 2,000 people, mainly elderly, still die from the … Japan,United Kingdom : Teijin Pharma and Pulmagen Therapeutics Sign … Teijin to develop and market bronchial asthma drug in Japan |
View full post on asthma – Google News